Clinical trials: Melanoma, Stage I
Malignant Melanoma
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
RATIONALE:Anti-melanoma activity of Ipilimumab both as a single therapy and in association with melanoma peptides has been shown as well as synergy between radiation therapy and anti-CTLA-A mAb in several tumor animal models for…
- Trial name
- Mel-Ipi-Rx (NCT01557114)
- Testing
- Ipilimumab, Radiotherapy
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumors
Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab
HBM4003 in combination with Toripalimab. The expected duration of treatment for each subject will vary according to the number of cycles completed; the number of cycles will depend on whether the subject benefits from the…
- Trial name
- NCT04727164
- Testing
- HBM4003 and Triprilimab
- Volunteers
- 61 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Melanoma
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling pathways are not redundant.
- Trial name
- NCT04756934
- Testing
- HX008, LP002
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
Cutaneous Melanoma, Stage II, Cutaneous Melanoma
Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma
The primary goal of this clinical trial is to is to compare the rate of positive peripheral margins in wide local excision (WLE) performed to allow for comprehensive peripheral and deep margin assessment (CPDMA) assessment versus…
- Conditions
- Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
- Trial name
- NCT07869381
- Testing
- Wide Local Excision
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- University of Nebraska
Malignant Melanoma
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma.
- Trial name
- NCT01522664
- Testing
- DEDN6526A
- Where
- 6 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Recurrent Melanoma, Stage IIIA Melanoma
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is metastatic or that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT01835184
- Testing
- cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897481
- Testing
- gene expression analysis, mutation analysis, diagnostic laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Malignant Melanoma
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
PRIMARY OBJECTIVES: Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs . SECONDARY OBJECTIVES:Determine immunological response to the vaccine (induction of specific T-cell response) and…
- Trial name
- NCT01278940
- Testing
- Dendritic Cells (DC) malignant melanoma, IL-2
- Volunteers
- 31 people
- Sponsor
- Oslo University Hospital
Kidney Cancer, Melanoma (Skin)
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally…
- Trial name
- NCT00492440
- Testing
- recombinant interleukin-7, gene expression analysis, polymerase chain reaction
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytheris SA
Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune…
- Trial name
- NCT04653038
- Testing
- MGD013
- Where
- 13 sites in China
- Volunteers
- 92 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to…
- Conditions
- Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm
- Trial name
- NCT03590054
- Testing
- Abexinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rahul Aggarwal
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
This phase I trial studies the side effects and the best dose of Akt inhibitor MK2206 together with hydroxychloroquine in treating patients with advanced solid tumors, melanoma, prostate or kidney cancer.
- Conditions
- Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- NCT01480154
- Testing
- Akt Inhibitor MK2206, Hydroxychloroquine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are…
- Trial name
- NCT03101254
- Testing
- LY3022855, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Melanoma, Neoplasms
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
This open-label, multi-center, three-period, one sequence study will investigate the effect of ketoconazole on the pharmacokinetics of vemurafenib in patients with unresectable BRAFV600-mutation positive metastatic melanoma or…
- Trial name
- NCT01765556
- Testing
- ketoconazole, vemurafenib
- Sponsor
- Hoffmann-La Roche
Melanoma, Advanced Melanoma
Study of Temzolomide and Gleevec in Advanced Melanoma
This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients…
- Trial name
- NCT00667953
- Testing
- Gleevec, Temodar
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma, Solid Tumors
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
This is a 5-part dose-finding and preliminary efficacy study of pembrolizumab (Pembro) + dabrafenib (D) + trametinib (T) for participants with advanced melanoma and solid tumors.
- Trial name
- NCT02130466
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03677739
- Testing
- Informational Intervention, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer.
- Trial name
- NCT01078961
- Testing
- bortezomib, sorafenib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Melanoma, Stage I, Melanoma, Stage II
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.
- Conditions
- Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III
- Trial name
- MelanooMSOT (NCT05467137)
- Testing
- MSOT
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen